Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly bacillus Calmette-Guérin (BCG) or alternating BCG and interferon-α2b instillations: prospective randomised Fi
暂无分享,去创建一个
P. Boström | S. Aaltomaa | M. Vaarala | E. Kaasinen | J. Kallio | R. Järvinen | M. Seppänen | J. Viitanen | E. Rintala | T. Marttila | T. Liukkonen | V. Puolakka | K. Tuhkanen
[1] Maximilian Burger,et al. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. , 2017, European urology.
[2] L. Martínez-Piñeiro,et al. Sequential combination of mitomycin C plus bacillus Calmette-Guérin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: final outcome of CUETO 93009, a randomized prospective trial. , 2015, European urology.
[3] M. Babjuk,et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. , 2013, European urology.
[4] R. Sylvester,et al. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. , 2013, European urology.
[5] E. Kaasinen,et al. Long-term results of maintenance treatment of mitomycin C or alternating mitomycin C and bacillus Calmette–Guérin instillation therapy of patients with carcinoma in situ of the bladder: A subgroup analysis of the prospective FinnBladder 2 study with a 17-year follow-up , 2012, Scandinavian journal of urology and nephrology.
[6] M. Shoukri,et al. Co‐administration of intravesical bacillus Calmette‐Guérin and interferon α‐2B as first line in treating superficial transitional cell carcinoma of the urinary bladder a , 2011, BJU international.
[7] M. Stockler,et al. Re: Willem Oosterlinck, Ziya Kirkali,Richard Sylvester, et al. Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTCGenito-urinary Group Randomize , 2011, European urology.
[8] Kehu Yang,et al. Intravesical Bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancer. , 2011, The Cochrane database of systematic reviews.
[9] A. Bohle. Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC genito-urinary group randomized phase 2 trial (30993) , 2011 .
[10] C. Busch,et al. Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTC genito-urinary group randomized phase 2 trial (30993). , 2011, European urology.
[11] D. Lamm,et al. Bacillus Calmette-Guérin with or without interferon α-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer. , 2010, The Journal of urology.
[12] A. Sankila,et al. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up. , 2009, European urology.
[13] P. Bendahl,et al. Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study. , 2009, European urology.
[14] V. Boddi,et al. Can early single dose instillation of epirubicin improve bacillus Calmette-Guerin efficacy in patients with nonmuscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study. , 2008, The Journal of urology.
[15] Brian J. Smith,et al. Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. , 2006, Urologic oncology.
[16] K. Jauhiainen,et al. Cytostatic effect of different strains of Bacillus Calmette-Guérin on human bladder cancer cells in vitro alone and in combination with mitomycin C and Interferon-α , 2004, Urological Research.
[17] P. Malmström,et al. Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a nordic study. , 2003, European urology.
[18] Alberto Redaelli,et al. The health economics of bladder cancer: a comprehensive review of the published literature. , 2003, PharmacoEconomics.
[19] A. Böhle,et al. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. , 2003, The Journal of urology.
[20] E. Kaasinen,et al. Perioperative single dose instillation of epirubicin or interferon-alpha after transurethral resection for the prophylaxis of primary superficial bladder cancer recurrence: a prospective randomized multicenter study--FinnBladder III long-term results. , 2002, The Journal of urology.
[21] E. Kaasinen,et al. Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma. , 2002, European urology.
[22] A. Böhle. Perioperative single dose instillation of epirubicin or interferon-alpha after transurethral resection for the prophylaxis of primary superficial bladder cancer recurrence: a prospective randomized multicenter study - Finnbladder III long-term results. , 2002, International braz j urol : official journal of the Brazilian Society of Urology.
[23] M. O'Donnell,et al. Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed. , 2001, The Journal of urology.
[24] A. Ezzat,et al. Prospective phase II trial of alternating intravesical Bacillus Calmette‐Guérin (BCG) and Interferon alpha IIB in the treatment and prevention of superficial transitional cell carcinoma of the urinary bladder: Preliminary results , 2000, Journal of surgical oncology.
[25] E. Kaasinen,et al. Weekly mitomycin C followed by monthly bacillus Calmette-Guerin or alternating monthly interferon-alpha2B and bacillus Calmette-Guerin for prophylaxis of recurrent papillary superficial bladder carcinoma. , 2000, The Journal of urology.
[26] Robert Gray,et al. A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .
[27] B. Norlén,et al. 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group. , 1999, The Journal of urology.
[28] J. Witjes,et al. Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer. , 1998, The Journal of urology.
[29] P. Schellhammer,et al. Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study. , 1995, Urologic oncology.